AND SPECIFIC AIMS: NETWORK RESOURCE Pharmacogenomics is a multidisciplinary science;it has also become a data-intensive science. Therefore, it requires increasingly clear annotation and representation of phenotypes (disease, adverse event, or clinical and physiological outcomes) to support data integration and cross-database analyses. In fact, the consistent and interpretable characterization of drug-related phenotypes, including treatment response, adverse events, and clinical outcomes, has become a rate-limiting factor in large-scale pharmacogenomic research. We propose a PGRN Network Resource focused on the codification of standardized phenotype definitions and relationships, in coordination with other established government-funded efforts, with a clear and constant focus on pharmacogenomics. Because the standardized representation of phenotypes depends on standards, our first two aims focus on making vocabularies and ontologies (computationally formal vocabularies) about clinical and physiologic concepts accessible and usable to the PGRN community. While necessary, such terminological resources are pedantic absent methods and machinery to integrate them into practical phenotypes. Additionally, we will foster the creation of pharmacogenomically relevant value sets, drawn from standards-based terminologies that satisfy relevant domain-specific requirements, such as anatomy, drug names, or gene names. Finally, a PGRN resource must support outreach to PGRN members and the larger pharmacogenomics community to establish standard phenotypes, stnjctured in a way that these pharmacogenomically relevant phenotypes conform to community and government standards, provide grounding for extension to related conditions, and serve as examples for the broader scientific community. We anticipate that this resource will help to enable consistent and comparable large-scale phenotyping for pharmacogenomics.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19GM061388-15
Application #
8683188
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Ho, Ada Man-Choi; Qiu, Yanyan; Jia, Yun-Fang et al. (2016) Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice. Alcohol Clin Exp Res 40:1531-9
Tamm, Riin; Mägi, Reedik; Tremmel, Roman et al. (2016) Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: a meta-analysis of three genome-wide association studies. Clin Pharmacol Ther :
Ingle, James N; Xie, Fang; Ellis, Matthew J et al. (2016) Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Res 76:7012-7023
Aziz, Ayesha; Kawamoto, Kensaku; Eilbeck, Karen et al. (2016) The genomic CDS sandbox: An assessment among domain experts. J Biomed Inform 60:84-94
Cairns, Junmei; Ung, Choong Yong; da Rocha, Edroaldo Lummertz et al. (2016) A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes. Sci Rep 6:37003
Chapman, Judith-Anne W; Shepherd, Lois E; Ingle, James N et al. (2016) Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. Breast Cancer Res Treat 156:343-9
Caraballo, Pedro J; Hodge, Lucy S; Bielinski, Suzette J et al. (2016) Multidisciplinary model to implement pharmacogenomics at the point of care. Genet Med :
Deng, Min; Yang, Xu; Qin, Bo et al. (2016) Deubiquitination and Activation of AMPK by USP10. Mol Cell 61:614-24
Park, Jae-Hyun; Jang, Miran; Tarhan, Yunus Emre et al. (2016) Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol 49:471-8
Kalman, L V; Agúndez, Jag; Appell, M Lindqvist et al. (2016) Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin Pharmacol Ther 99:172-85

Showing the most recent 10 out of 122 publications